InvestSMART

Antisense Therapeutics Limited (ASX: ANP) - Announcements

Current share price for ANP : $0.058 0.003 (4.92%)+

ASX company news and announcements for Antisense Therapeutics Limited (ANP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Antisense Therapeutics Limited (ANP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Antisense Therapeutics Limited (ANP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Antisense Therapeutics Limited (ANP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 ANP Updates on US Regulatory Plans for ATL1102 in DMD 12 Aug 2021 8:48AM $0.200 $0.058 fallen by 71%
$52 Quarterly Report and Appendix 4C 29 Jul 2021 9:28AM $0.205 $0.058 fallen by 71.71%
$52 Antisense Therapeutics transitions to new Board Chair 28 Jul 2021 9:06AM $0.190 $0.058 fallen by 69.47%
$52 ANP and MCRI new R&D collaboration for ATL1102 28 Jun 2021 9:56AM $0.190 $0.058 fallen by 69.47%
$52 ATL1102 for DMD EMA PIP feedback and FDA regulatory progress 22 Jun 2021 9:09AM $0.195 $0.058 fallen by 70.26%
$52 US FDA Feedback on Type C Meeting for ATL1102 in the US 1 Jun 2021 9:58AM $0.205 $0.058 fallen by 71.71%
$52 Manufacture of ATL1102 clinical supplies for Phase IIb trial 26 May 2021 9:49AM $0.200 $0.058 fallen by 71%
$52 Appendix 2A & Cleansing Notice 7 May 2021 6:25PM $0.175 $0.058 fallen by 66.86%
$52 Proposed issue of Securities - ANP 7 May 2021 6:05PM $0.175 $0.058 fallen by 66.86%
$52 Quarterly Report and Appendix 4C 28 Apr 2021 9:54AM $0.200 $0.058 fallen by 71%
$52 US FDA Type C Meeting for ATL1102 in DMD 23 Apr 2021 9:51AM $0.200 $0.058 fallen by 71%
$52 Initial Director's Interest Notice - CG 24 Mar 2021 7:08PM $0.200 $0.058 fallen by 71%
$52 Antisense Therapeutics appoints new Non-Executive Director 22 Mar 2021 9:29AM $0.205 $0.058 fallen by 71.71%
$52 Appendix 3G 19 Mar 2021 7:58PM $0.205 $0.058 fallen by 71.71%
$52 FDA Rare Disease Day 2021 4 Mar 2021 8:56AM $0.160 $0.058 fallen by 63.75%
$52 Jett Foundation 4th Annual Rare Disease Day 26 Feb 2021 9:39AM $0.180 $0.058 fallen by 67.78%
$52 ATL1102 DMD Paediatric Investigation Plan submitted to EMA 25 Feb 2021 8:47AM $0.170 $0.058 fallen by 65.88%
$52 Company Secretary Appointment 24 Feb 2021 4:37PM $0.170 $0.058 fallen by 65.88%
$52 Half Yearly Report and Half Year Accounts 24 Feb 2021 4:30PM $0.170 $0.058 fallen by 65.88%
$52 ANP meeting with US FDA granted for ATL1102 in DMD 15 Feb 2021 9:04AM $0.225 $0.058 fallen by 74.22%
$52 Quarterly Update and Appendix 4C 28 Jan 2021 9:16AM $0.215 $0.058 fallen by 73.02%
$52 Appendix 2A 15 Jan 2021 4:45PM $0.210 $0.058 fallen by 72.38%
$52 Proposed issue of Securities - ANP 15 Jan 2021 4:25PM $0.210 $0.058 fallen by 72.38%
$52 Change of Registered Office and Principal Place of Business 14 Jan 2021 12:40PM $0.195 $0.058 fallen by 70.26%
$52 Ceasing to be a substantial holder 11 Jan 2021 4:49PM $0.180 $0.058 fallen by 67.78%

151 - 175 of 707 results

Page 7 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.